Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N. Marotte L, et al. Among authors: beauvais t. J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. J Immunother Cancer. 2020. PMID: 32001504 Free PMC article.
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Marotte L, Capitao M, Deleine C, Beauvais T, Cadiou G, Perrin J, Chérel M, Scotet E, Guilloux Y, Bruchertseifer F, Morgenstern A, Jarry A, Gaschet J, Labarriere N. Marotte L, et al. Among authors: beauvais t. Oncoimmunology. 2021 Jun 27;10(1):1940676. doi: 10.1080/2162402X.2021.1940676. eCollection 2021. Oncoimmunology. 2021. PMID: 34239774 Free PMC article.
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N. Simon S, et al. Among authors: beauvais t. J Immunother Cancer. 2020 Nov;8(2):e001631. doi: 10.1136/jitc-2020-001631. J Immunother Cancer. 2020. PMID: 33188038 Free PMC article.
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.
Dréno B, Khammari A, Fortun A, Vignard V, Saiagh S, Beauvais T, Jouand N, Bercegay S, Simon S, Lang F, Labarrière N. Dréno B, et al. Among authors: beauvais t. Cancer Immunol Immunother. 2021 Oct;70(10):3015-3030. doi: 10.1007/s00262-021-02961-0. Epub 2021 Jun 12. Cancer Immunol Immunother. 2021. PMID: 34120214 Free PMC article. Clinical Trial.
Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology.
Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcaïs A, Malloci M, Fanton d'Andon M, Beauvais T, Labarriere N, Jeannin P, Abel L, Saint-André JP, Croué A, Delneste Y, Boneca IG, Marsollier L, Marion E. Foulon M, et al. Among authors: beauvais t. PLoS Pathog. 2020 Dec 18;16(12):e1009107. doi: 10.1371/journal.ppat.1009107. eCollection 2020 Dec. PLoS Pathog. 2020. PMID: 33338061 Free PMC article.
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.
Cadiou G, Beauvais T, Marotte L, Lambot S, Deleine C, Vignes C, Gantier M, Hussong M, Rulli S, Jarry A, Simon S, Malissen B, Labarriere N. Cadiou G, et al. Among authors: beauvais t. Oncoimmunology. 2024 Jul 8;13(1):2376782. doi: 10.1080/2162402X.2024.2376782. eCollection 2024. Oncoimmunology. 2024. PMID: 38983599 Free PMC article.